What Synacthene Retard Treats: Main Uses and Benefits

This medication is commonly used in situations involving certain distressing symptoms. It is applied across domains where additional symptomatic support is needed, such as in conditions characterized by periods of heightened symptoms or systemic imbalance.

This therapeutic approach is relevant for managing symptoms related to inflammatory or irritative states in severe, chronic autoimmune and inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, severe inflammatory bowel disease, and specific conditions like West's syndrome (Infantile Spasms). It is used for managing symptoms that may appear suddenly or intensify over time.

“This medication is considered relevant for managing symptoms that interfere with daily comfort, provides support during difficult symptomatic episodes.”

The prolonged therapeutic profile may support a prolonged symptomatic benefit, helping patients with chronic conditions manage symptom fluctuations. Furthermore, it is applied in clinical settings for the diagnostic assessment of adrenal gland function and assists with functional stability.

---

Quick Fact: Relief for Inflammatory Symptoms

Area of Use	Symptom/Condition Category	Primary Benefit
Rheumatology	Systemic inflammation, joint swelling	Contributes to easing the overall symptom load
Pediatric Neurology	Recurrent, refractory seizure patterns	Supports patients during difficult episodes by easing distress
Endocrinology	Suspected adrenal gland dysfunction	Supports the process of clinical assessment

Regulatory References

1. New Zealand Medsafe Data Sheet on Synacthen

Population Eligibility and Contraindications

Official regulatory labeling defines specific populations who are eligible for Synacthene Retard (Tetracosactide) and those who are strictly prohibited from use. Eligible populations typically include adults and children aged five years and older under standard labeled conditions.

Absolute Non-Eligibility (Contraindications)

Use is contraindicated in patients with specific health conditions or sensitivities. These include individuals with known hypersensitivity to tetracosactide or ACTH, and those with:

• Acute psychosis
• Cushing's syndrome or Primary adrenocortical insufficiency
• Infectious diseases (untreated bacterial, fungal, or viral)
• Active or latent peptic ulcer
• Refractory congestive heart failure

Age-Related and Special Population Restrictions

Age Group / Status	Official Regulatory Status
Premature Babies/Neonates	Contraindicated (due to excipient safety)
Infants (1 month to 3 years)	Not recommended (due to excipient safety)
Pregnancy	Conditional use (Only if benefit outweighs potential risk)
Renal/Hepatic Impairment	Use not established (No specific studies performed)

The medicine is also contraindicated for the treatment of asthma and other allergic conditions due to an officially recognized risk of anaphylactic reactions. Caution is advised for breastfeeding women as excretion into human milk is unknown.

Interactions with other medicines and products

Interaction Scope: Pharmacodynamic and Toxicological Effects

The official interaction profile of Tetracosactide is primarily structured around its pharmacodynamic effect: the stimulation of endogenous corticosteroid production. This effect necessitates specific clinical attention for several product classes. Due to the increase in plasma glucocorticoids, patients using antidiabetic medications may require potential adjustments to their dosage regimen. Similarly, the mineralocorticoid effect may lead to fluid retention, which requires a potential dosage adjustment for antihypertensive drugs. A separate toxicological interaction is documented with certain anticonvulsants, such as phenytoin, where co-administration may increase the risk of liver damage.

Interaction-Related Restrictions and Constraints

Regulatory authorities state that live virus vaccines must not be administered during Tetracosactide treatment due to the risk of immunosuppression. A prominent population-specific restriction is noted in the pediatric population, where co-administration with Valproate products is officially not recommended due to the documented risk of severe jaundice. For diagnostic purposes, a mandatory timing separation rule applies: substances such as Cortisone and Hydrocortisone must be avoided immediately prior to the Synacthen test to prevent interference and ensure accurate cortisol measurement.

A synthetic analog of adrenocorticotropic hormone (ACTH), Synacthene Retard mimics the action of endogenous ACTH on the adrenal cortex. The primary action is stimulating the production and release of glucocorticoids (like cortisol) and, to a lesser extent, mineralocorticoids from the adrenal gland.

Specifically, the mechanism involves binding to the melanocortin 2 receptor (MC2R) located on the plasma membrane of fasciculata and reticularis cells in the adrenal cortex. Upon binding, the G-protein coupled receptor activates adenylyl cyclase, leading to an increase in intracellular cyclic AMP (cAMP) levels. The elevated cAMP then acts as a second messenger, activating protein kinase A (PKA), which phosphorylates key enzymes involved in the steroidogenesis cascade. This results in enhanced conversion of cholesterol to pregnenolone, the rate-limiting step in corticosteroid synthesis, leading to the release of corticosteroids.

How to use Synacthene Retard — Official Administration Guidelines

Synacthene Retard (tetracosactide zinc injection) is a suspension formulated for use strictly via intramuscular (IM) injection. It is administered by a healthcare professional in a controlled clinical setting, with the dosage and frequency highly individualized based on the patient's condition and response to therapy. Self-injection is not recommended.

Official Administration Protocol

Administration Scope	Details
Route of Administration	Intramuscular (IM) injection only.
Dosing Schedule (General)	Initial doses may vary (e.g., 0.25 mg to 1 mg). Maintenance doses are typically 1 mg every 2 to 8 days, adjusted to the lowest effective level.
Age-Group Rules	Doses for children must be reduced. Typical recommendations range from 0.25 mg to 1 mg per injection, with the frequency determined by the treating physician.
Preparation	The product is a suspension for injection; no dilution or reconstitution steps are explicitly stated.
Special Conditions	The injection must be performed under medical supervision, and the patient must be observed for a period following administration due to the potential for hypersensitivity reactions. Treatment necessitates continuous clinical and laboratory monitoring (e.g., blood pressure and electrolytes).

Procedural Summary

The official procedure involves the physician determining the precise starting dose and frequency, followed by the IM administration of the suspension. The frequency pattern is intermittent, ranging from daily (in some acute/diagnostic protocols) to weekly or less often for maintenance. The dose is then gradually adjusted (tapered) by the physician to prevent relative insufficiency of the pituitary-adrenal axis upon discontinuation.

Research evidence / Overview of studies for Synacthene Retard

Evidence for Diagnostic Assessment of Adrenal Function

Research for this specific application centers on its role as a diagnostic tool to investigate the functional capacity of the adrenal glands. Studies conducted during this research examined various diagnostic accuracy studies and cross-sectional research to investigate the consistency of the test protocol. This involved monitoring physiological changes, specifically measuring peak plasma or salivary cortisol concentrations at fixed intervals after the injection. Findings from this research described consistent patterns of cortisol response and provided data used to describe the functional status of the adrenal gland. These observations align with the test's application as a standardized procedure for evaluating the adrenal response system.

Evidence for Use in Infantile Spasms (West's Syndrome)

The research base for the therapeutic use in Infantile Spasms includes controlled studies, often summarized in systematic reviews. Studies explored how this medicine was evaluated in infants diagnosed with this specific, rare form of epilepsy. Researchers primarily monitored two main outcomes: the cessation of epileptic spasms as observed clinically and the resolution of hypsarrhythmia (an abnormal brain wave pattern) measured by electroencephalogram (EEG). Short-term controlled studies and reviews reported how spasm frequency and EEG patterns changed during the study period. However, certainty remains low regarding long-term cognitive and neurodevelopmental outcomes, as follow-up durations were limited in many initial clinical assessment trials.

Research Gaps and Areas of Uncertainty

The available research provides context but also highlights what is still uncertain across the indications. Evidence quality varies across studies, with some indications supported by high-quality controlled studies and others relying more on observational data. Comparative evidence is lacking in some areas, particularly concerning the long-term relative performance of the depot formulation against the newest alternative therapies. Finally, optimal protocols—such as the ideal treatment duration or maintenance strategies—are not fully established and remain the subject of ongoing research.

Common questions about Synacthene Retard (FAQ)

Q: How quickly can I expect Synacthene Retard to start working?

Official documents describe Synacthene Retard as a 'Depot' or 'Retard' formulation. This means the active ingredient is released slowly and works over a longer period compared to short-acting versions of the medicine. The specific timing of the therapeutic effect is highly individualized and is determined by the healthcare provider based on the condition being addressed.

Q: Are the side effects of Synacthene Retard generally temporary?

The duration of observed side effects may vary depending on the specific reaction. Official product information states that systemic effects, such as potential changes to bone density (osteoporosis) or eye disorders (cataracts), are primarily associated with prolonged periods of therapeutic use.

Q: Does Synacthene Retard cause weight gain or changes in appetite?

Regulatory documents indicate that possible systemic effects of the medicine include increased appetite and weight gain. This is related to the medicine's mechanism of stimulating the body's natural hormones.

Q: Can Synacthene Retard affect mood or cause emotional changes?

Official safety information documents list psychiatric disorders among the potential adverse effects. Reported effects include changes in personality, mood swings, euphoria, and severe depression.

Q: Can Synacthene Retard interfere with flu shots or other vaccinations?

Regulatory documents strictly state that live virus vaccines must not be administered during treatment with this medicine. Caution is advised for other immunization procedures because there is a potential for a decreased antibody response.

Q: Can Synacthene Retard affect sleep patterns?

Official regulatory documents report that difficulty sleeping, or insomnia, is a potential undesirable effect. This reaction is categorized under psychiatric disorders in the official safety profile.

Q: Is there a known interaction between Synacthene Retard and birth control pills?

Official documents describe that estrogen-containing drugs, such as some birth control pills, can increase cortisol-binding proteins. This effect may interfere with and may result in higher readings when measuring blood cortisol, particularly during diagnostic testing with this medicine.

Q: Who is usually considered eligible to receive Synacthene Retard?

The medicine is officially authorized for two main roles: the diagnostic assessment of adrenal gland function, and the therapeutic treatment of specific conditions. These therapeutic uses include certain rheumatological, collagen, and neurological diseases (such as Infantile Spasms). Use is determined based on the patient's diagnosed condition and the absence of specific contraindications.

Q: Can children or teenagers be treated with Synacthene Retard?

Synacthene Retard is indicated for use in children for certain therapeutic purposes, but with important age constraints. It is generally not recommended for infants and young children between one month and three years old, primarily due to one of its excipients. Regulatory documents describe that the dosage for older children generally requires reduction.

Q: Is Synacthene Retard prescribed during pregnancy or while breastfeeding?

Regulatory guidance describes that the medicine is used during pregnancy only if the potential benefit to the patient justifies the potential risk to the fetus. It is not known whether the active ingredient, tetracosactide, passes into breast milk.

Q: If I have diabetes, can I still use Synacthene Retard?

The medicine stimulates the production of hormones that can affect blood sugar levels. Official documents state that patients receiving medication for diabetes may require antidiabetic dosage readjustment and close monitoring by their healthcare provider if Synacthene Retard treatment is initiated.

Q: Is Synacthene Retard typically a short-term or long-term treatment?

Treatment duration is determined by the healthcare provider based on the individual condition. Research documentation often describes use for certain conditions, such as Infantile Spasms, in terms of short-term treatment. Furthermore, some systemic side effects are officially associated with prolonged therapeutic use.

Q: Can Synacthene Retard be used for purposes outside of endocrine disorders?

Yes. While the medicine acts on the endocrine system by stimulating hormone production, official product indications authorize its therapeutic use in several non-endocrine conditions, including specific rheumatological, collagen, and neurological diseases.

Q: Are there alternatives to Synacthene Retard that work similarly?

Official clinical reviews and research papers for specific conditions, such as Infantile Spasms, do list other therapeutic options. These can include specific corticosteroids or other non-hormonal anti-seizure medications.

Q: Are there special precautions for elderly patients using Synacthene Retard?

Official regulatory documents specifically state there is no evidence to suggest that the dosage needs to be different in elderly patients compared to other adults.

Q: How is the risk of infection described for patients on Synacthene Retard?

Regulatory documents state that the medicine is contraindicated in patients with untreated bacterial, fungal, or viral infections. Official warnings note that latent (inactive) infections, such as tuberculosis, may also become reactivated during treatment.

Q: Does Synacthene Retard have an impact on blood pressure?

The safety profile includes reports of hypertension, which is high blood pressure, and peripheral edema, which is fluid retention. These are potential adverse reactions that reflect the stimulating effect of the medicine on the body's natural hormones.

Q: Are there common reasons why a patient might need to stop using Synacthene Retard?

The treatment protocol describes immediate discontinuation if the patient experiences severe hypersensitivity reactions, such as anaphylactic shock. Discontinuation for other reasons is performed gradually and under the supervision of the prescribing physician when the underlying condition no longer requires treatment.

Q: Is it important to monitor bone density while using this medication?

Official safety information notes that musculoskeletal disorders, including osteoporosis, are potential effects associated with prolonged therapeutic use of the medicine, highlighting a risk to be aware of.

Q: Is there a warning about driving or operating machinery while on this treatment?

Regulatory documents contain a warning that if patients experience side effects such as dizziness, caution is necessary when driving or operating machinery.

Q: Does Synacthene Retard cause stomach upset or digestive issues?

Gastrointestinal disorders are included in the safety profile of the medicine. Documented reports include severe effects such as peptic ulceration, and associated symptoms like stomach pain, nausea, and vomiting.

Q: Are there specific patient groups where Synacthene Retard is generally not recommended?

Regulatory documents describe patient groups where the medicine is contraindicated, including those with a known hypersensitivity to the drug, active psychosis, untreated systemic infections, active peptic ulceration, or Cushing's syndrome.

How to Store and Dispose of Synacthene Retard?

Synacthene Retard must be stored according to strict regulatory conditions to ensure its stability. The medication must be kept in a refrigerator at a temperature between 2 C and 8 C.

To maintain product integrity, the ampoules must remain in the outer carton to protect the contents from light. It is essential to keep the product out of the sight and reach of children.

The injectable suspension is for immediate use once opened. Any remaining solution after the injection must be discarded.

Expired or unused medicine must not be disposed of via household waste or wastewater. It must be returned to a pharmacy or discarded according to local requirements for pharmaceutical waste.